Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
133
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

52
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
52
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

43
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
43
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

85
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
85
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

920
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
920
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

230
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiologists' perspectives on sociocultural and structural factors shaping cardiovascular genetic testing.

medRxiv : the preprint server for health sciences·2026
Same author

The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment.

Public health genomics·2026
Same author

Blood pressure screening event at hispanic community organization yields positive screenings and links to primary care.

BMC public health·2026
Same author

Predictors of Detectable Viral Load among Adolescents with HIV in Low Resource Settings who are Receiving Care in Youth-Friendly Clinics.

AIDS (London, England)·2026
Same author

A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals.

Circulation·2026
Same author

Health actions after direct-to-consumer genetic testing for medically actionable conditions.

Genetics in medicine open·2026
Same journal

RETRACTED: Zito Marino et al. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1993.

Journal of personalized medicine·2026
Same journal

Correction: Rao et al. Ensemble Deep-Learning-Based Prognostic and Prediction for Recurrence of Sporadic Odontogenic Keratocysts on Hematoxylin and Eosin Stained Pathological Images of Incisional Biopsies. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1220.

Journal of personalized medicine·2026
Same journal

Three-Dimensional Bronchovascular Modelling in Sublobar Pulmonary Resection: A Tool for Personalised Thoracic Surgery.

Journal of personalized medicine·2026
Same journal

Serum Albumin, Globulin and Albumin-Globulin Ratios as Biomarkers of Clinical Outcomes in COVID-19 Pneumonia.

Journal of personalized medicine·2026
Same journal

New Advances and Perspectives in Ophthalmology: Progress and Modern Challenges Toward Personalized Eye Care.

Journal of personalized medicine·2026
Same journal

Bridging Ancestry-Stratified Bias in Pharmacogenomics AI: Toward Metabolomics-Inclusive Multi-Omics Precision Medicine.

Journal of personalized medicine·2026
See all related articles

Related Experiment Video

Updated: Sep 26, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH Protocol.

Laney K Jones1,2, Marc S Williams2, Ilene G Ladd2

  • 1Heart and Vascular Institute, Geisinger, Danville, PA 17821, USA.

Journal of Personalized Medicine
|April 23, 2022
PubMed
Summary
This summary is machine-generated.

The CARE-FH study implements strategies to improve Familial Hypercholesterolemia (FH) diagnosis in primary care. This aims to identify individuals with FH early, preventing cardiovascular events.

Keywords:
cholesterol screeningfamilial hypercholesterolemiaimplementation sciencepreventionprimary care

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Experiment Videos

Last Updated: Sep 26, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Area of Science:

  • Implementation Science
  • Cardiovascular Disease Prevention
  • Public Health

Background:

  • Familial Hypercholesterolemia (FH) is an underdiagnosed genetic condition leading to premature cardiovascular disease.
  • Early identification and management of FH can significantly reduce atherosclerotic cardiovascular disease (ASCVD) events.
  • Current diagnostic evaluation rates for FH in primary care settings require improvement.

Purpose of the Study:

  • To enhance the diagnostic evaluation rates for Familial Hypercholesterolemia (FH) within an integrated health system.
  • To implement evidence-based guidelines for FH identification into routine primary care.
  • To assess the impact of implementation strategies on diagnostic rates and patient outcomes.

Main Methods:

  • The study employs implementation science principles and a stepped-wedge design across primary care settings.
  • Intervention strategies will be rolled out regionally to internal medicine, community medicine, and pediatric clinicians.
  • Data collection will focus on diagnostic evaluation rates, implementation fidelity, service delivery, and health outcomes.

Main Results:

  • This phase focuses on trial design and the development of implementation strategies.
  • The second phase will analyze the intervention's impact on diagnostic evaluation rates.
  • Outcomes related to implementation, service delivery, and patient health will be evaluated.

Conclusions:

  • The CARE-FH study protocol is designed to improve FH diagnosis through primary care integration.
  • Successful implementation could lead to earlier identification and better management of FH patients.
  • This approach has the potential to reduce the burden of atherosclerotic cardiovascular disease associated with FH.